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Abstract
The COVID-19 pandemic poses an unprecedented health crisis in all socio-economic regions across the globe. While the pandemic has had 
a profound impact on access to and delivery of health care by all services, it has been particularly disruptive for the care of patients with life-
threatening noncommunicable diseases (NCDs) such as the treatment of children and young people with cancer.
The reduction in child mortality from preventable causes over the last 50 years has seen childhood cancer emerge as a major unmet health 
care need. Whilst survival rates of 85% have been achieved in high income countries, this has not yet been translated into similar outcomes 
for children with cancer in resource-limited settings where survival averages 30%. Launched in 2018, by the World Health Organization 
(WHO), the Global Initiative for Childhood Cancer (GICC) is a pivotal effort by the international community to achieve at least 60% survival 
for children with cancer by 2030.
The WHO GICC is already making an impact in many countries but the disruption of cancer care during the COVID-19 pandemic threatens 
to set back this global effort to improve the outcome for children with cancer, wherever they may live.
As representatives of the global community committed to fostering the goals of the GICC, we applaud the WHO response to the COVID-19 
pandemic, in particular we support the WHO’s call to ensure the needs of patients with life threatening NCDs including cancer are not com-
promised during the pandemic. Here, as collaborative partners in the GICC, we highlight specific areas of focus that need to be addressed 
to ensure the immediate care of children and adolescents with cancer is not disrupted during the pandemic; and measures to sustain the 
development of cancer care so the long-term goals of the GICC are not lost during this global health crisis.
Keywords: COVID-19, neoplasms, children, paediatric, policy, global
Introduction
The success of global public health measures over the last 50 years, particularly childhood immunisation, improved nutrition and infection 
prevention, has led to a marked global reduction in early childhood mortality. However, wherever the health of children improves from pre-
ventable causes, cancer in childhood inevitably emerges as a significant and unmet health care need [1].
Collectively, childhood cancers represent a major global child health burden. Each year at least 400,000 children and adolescents in the 0– 19 
age group develop cancer, a figure that is probably a serious underestimate due to a worldwide lack of access to cancer diagnosis and treat-
ment, and the lack of systematic cancer registration in many settings [2–4].
Cancers occurring during childhood and adolescence are clinically and biologically distinct from those seen in adults; and combined with their 
special developmental needs, children and adolescents with cancer have unique demands and experiences across the cancer journey. Over 
the last 50 years, the development of age-appropriate multidisciplinary care and cancer treatment based on research-informed international 
collaborative clinical trials have achieved a remarkable improvement in survival for children with cancer. These outcome benefits need not be 
limited to high-income countries; evidence shows that cancer treatment for children in many low- and middle-income countries is both cost 
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Launched in 2018, the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC) has mobilised the global child cancer 
community in a focused effort to improve the survival of children with cancer to over 60% by 2030; this truly transformative change has an 
initial focus on six common cancers: Acute lymphoblastic leukaemia, Burkitt lymphoma, Hodgkin lymphoma, Retinoblastoma, Wilms tumour 
and Low-grade glioma, and may save over 1 million lives by the turn of the next decade [6].
Unfortunately, the serious impact the COVID-19 pandemic (declared on 11 March 2020) has had on public health services worldwide pres-
ents a major barrier and a global challenge to maintaining the gains already achieved and may seriously impair future progress towards the 
long-term goals of the GICC.
Healthcare professionals caring for children and adolescents with cancer applaud the worldwide mobilisation of efforts to mitigate the SARS 
CoV-2 virus and treat those affected with COVID-19. However, we implore all agencies and health services to collaborate and ensure the 
current and future needs of children and adolescents with cancer are considered across all national and regional initiatives to respond to the 
COVID-19 pandemic.
This quest is not just for access to early diagnosis, cancer care and treatment, but also for improved and sustained access to the psychosocial 
support families require to ensure their child can be treated in a timely manner. Moreover, for the many children and young people world-
wide, who have life limiting diagnoses, we implore health services and health ministries to ensure timely access to palliative care especially 
the medication needed for the relief of pain and suffering.
Challenges posed by the COVID-19 pandemic
A survey of 155 countries released by the WHO on 1 June 2020 [7] shows the breadth of impact on health services for those with cancer and 
other noncommunicable diseases (NCDs), including the cancellation of elective health services (especially surgery and radiotherapy), short-
ages of essential medicines and delayed diagnostics, the overwhelming of hospital inpatient services and cancellation of essential outpatient 
services. This has been compounded by serious and ongoing healthcare staffing issues due to the direct and personal impact of COVID-19 
on the health and wellbeing of nursing, medical and allied professionals and their families. The WHO Pulse Survey released in August 2020 
confirmed this concerning trend across multiple disease areas [8].
Unlike a medical emergency where a life may be saved immediately, saving the life of a child or young person with cancer is a marathon, not 
a sprint, it takes many months of sustained and coordinated effort by multiple healthcare teams, and the child’s family, to achieve a life free 
of cancer.
Thus, the disruption of health services during this pandemic presents a serious challenge to maintaining and improving the care of children 
and adolescents with cancer, where equitable access to safe and affordable treatment is the cornerstone of the GICC.    
Several challenges presented by the COVID-19 pandemic are particularly relevant to the care of children and adolescents with cancer 
(Figure 1). We list them below with proposed mitigation strategies.
Reduced public health awareness of cancer
The developmental origins of childhood cancers and their presentation in early life preclude public health measures at primary prevention. 
Moreover, many childhood cancers develop rapidly with symptoms and clinical signs in young children, such as those seen in acute lympho-
blastic leukaemia, Burkitt lymphoma, that resemble, or occur concurrently, with those from other much more common causes, especially 
viral, bacterial and parasitic infections.  Thus, timely referral for the assessment and investigation of children and adolescents with unex-
plained symptoms or new clinical signs suggestive of cancer is crucial for making a diagnosis and commencing timely treatment.
However, the observed reduction since the start of the pandemic in referrals of children with cancer symptoms, especially those with solid 
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Figure 1. COVID-19 impact on childhood cancer.
Mitigation strategy: Health services and Health Ministries should implement or strengthen public health measures to raise awareness of 
cancer in children and adolescents. National ‘Early Warning Signs’ programmes are proven to be effective at encouraging parents and local 
healthcare providers to seek advice and early referral for children with possible cancer [11–14]. 
Parents need reassurance that it is both necessary and safe for them to have their child’s symptoms investigated as soon as possible and 
practical.
Treatment interruption, treatment delays and modification
The cure of cancer in children and adolescents is achieved by the timely and coordinated delivery of multimodal treatment including chemo-
therapy, surgery and radiotherapy (where indicated). The key to the successful treatment of childhood cancer is its sequencing and cadence; 
this means maintaining the intensity of treatment, with minimal disruption or delay to systemic chemotherapy, and the delivery of interca-
lated local therapy with surgery and/or radiotherapy. Delayed, interrupted or modified chemotherapy, deferred surgery and failure to provide 
appropriately timed radiotherapy reduce the chance of achieving disease remission, increase the chance of treatment failure and the raise the 
prospect of a premature or preventable death.
In response to the pandemic emergency, the International Society of Paediatric Oncology (SIOP) collaborated with St Jude Children’s Research 
Hospital to establish an International COVID-19 Registry to record prospectively the impact of COVID-19 infection in children with cancer. 
As of October 2020, the 30-day mortality of the 730 cases of children with cancer with complete follow-up was 5% [15] and significantly 
higher than children without cancer. Of equal concern is the observation from surveys of paediatric oncology services that planned treat-
ments for non-COVID-19 infected patients on active treatment are withheld, unavailable or postponed despite recommendations of the 
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Mitigation strategy: It is crucially important that health care providers maintain and support cancer services and ensure they can provide 
consistent and timely multimodal treatment while protecting patients and staff from infection [18–21]. Collaborative data registries, such 
as the International COVID-19 Registry, can provide the evidence needed for assessing the impact of the pandemic on cancer services and 
identify areas needing intervention. Consensus expert guidance and recommendations have been published previously from international 
organisations [16]: any local or regional adaptation of treatment due to shortages of essential medicines or other resource constraints should 
be limited and wherever possible and agreed by the local healthcare teams in consultation with parents.
Decreased psychosocial support for parents, families and healthcare staff
The true impact of the pandemic on the families of children with cancer is unknown but anecdotal experience across the globe suggests the 
effect has been severe and has brought the need for access to psychosocial support to the fore. Moreover, the access and availability of pal-
liative care support and symptoms relief for end-of-life care also appears to have been severely compromised during the pandemic.
Without affordable access to public transport or money to pay for travel, many families face the stark reality of their child not receiving any 
treatment for cancer. For families with little or no income, the need to travel long distances for treatment without any support for accom-
modation, or access to food, and other essentials is the source of extreme stress, raising the risk of treatment abandonment [22], medically 
induced poverty and preventable death.
Mitigation strategy: Healthcare teams, health services and support organisations need to ensure families have access to ongoing psychosocial 
support, during and after the pandemic. 
Where children and adolescents develop life-limiting cancer or end-of-life complications, access to palliative care including access to essen-
tial medications for pain and symptom relief is vital for compassionate treatment and comfort care.
It is also essential for nursing, medical and allied health staff to be provided with ongoing support by their employers for they face the dual 
challenge of caring for their patients while needing to care for themselves and their own families during this crisis.
Disruption to essential cancer medicines access and supply
Of urgent concern is the anticipated disruption to supply and ongoing shortages of essential cancer chemotherapy and supportive care 
medicines which are the mainstay of curative treatment in children [7, 23]. The supply and distribution of essential cancer medicines has 
always been fragile and erratic in many resource-limited settings and this has been compounded by the need to redirect limited funding 
and ‘manpower’ to the supply of personal protective equipment (PPE) and other consumables for the care of adult patients with COVID-19.
Efforts to ensure access to drugs on the WHO Essential Medicines List for children and those proposed in the paediatric review of the 
Essential Medicines List for cancer [24, 25] are vital to ensure curative care can be delivered to as many children in as many clinical settings 
as possible.
Mitigation strategy: Government Health Ministries need to ensure their national approved drug lists include those required to treat children 
(and adults) with cancer, and their drug regulatory authorities and purchasing agencies follow rigorous but streamlined regulatory process and 
pharmacovigilance to achieve sustained access to quality and affordable cancer chemotherapy. Special attention is required for the purchase 
and delivery of Asparaginase, a temperature sensitive therapeutic protein that is crucial for the cure of acute lymphoblastic leukaemia, which 
accounts for one third of all cases of cancer in childhood. Disrupted or delayed delivery, and loss of the cold-chain, could cause an unmea-
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Delayed diagnostic procedures and ‘local therapy’ with surgery and radiotherapy
Few childhood cancers, aside from the acute leukaemias and Non-Hodgkin Lymphoma, can be cured with chemotherapy alone, and almost 
all childhood solid tumours and brain tumours require ‘local therapy’—either surgery and/or radiotherapy—to either resect or irradiate the 
primary tumour. The diagnosis and staging of most childhood cancers involves diagnostic imaging and interventional biopsies often under 
general anaesthetic. The surgical resection of primary solid tumours in children may occur at diagnosis, but most often surgery follows a 
course of preoperative chemotherapy and may then be followed by radiotherapy and further chemotherapy. Access to diagnostic imaging 
and procedures for disease staging, and timely well-planned surgery and radiotherapy are crucial for achieving curative outcomes for many 
children and adolescents with cancer. 
The evidence of the impact of COVID-19 pandemic on the initial diagnosis and staging of children with cancer and access to ‘local therapy’ 
is emerging [26–29]. However, many centres are overwhelmed by the demand of COVID-19 patients, coupled with the need to minimise the 
risk of healthcare teams and patients to infection, and have severely restricted access to, or delayed and deferred, scheduled surgical proce-
dures and radiotherapy. The true long-term impact of these reduced services will be difficult to gauge especially the impact on the survival 
of children where there have been delays in local therapy for solid tumours.
Mitigation strategy: As regions begin to emerge from the COVID-19 crisis, the early return of full scheduled surgery lists and radiotherapy 
treatment will be essential for the continuity of care for children and adolescents with cancer. Planned cancer therapies, including radiation 
therapy should never be considered ‘elective’, since delays and gaps in care increase rate of relapse and decrease overall survival.
Towards collaborative solutions for emerging from the pandemic
The global community of child cancer healthcare professionals welcomed the statement of Dr Tedros Adhanom Ghebreyesus, Director-
General of the WHO, affirming that ‘It’s vital that countries find innovative ways to ensure that essential services for NCDs continue, even 
as they fight COVID-19’ [30]. The role of the WHO and member states in addressing the major health needs during this pandemic cannot be 
overstated. As international organisations dedicated to the care of children with cancer, we offer our support, advocacy and collaboration as 
we seek solutions on behalf of our patients, their families and our healthcare teams to this global crisis. 
We strongly advocate for the engagement of health services and health ministries with childhood cancer professionals and parent support 
organisations in the development and implementation of regional COVID-19 response strategies as we continue and emerge from the 
current pandemic and other health emergencies potentially arising in the future. It is also essential that pandemic crisis management has 
a connection with health care planning for NCDs, including paediatric cancer control. As stakeholders in child and adolescent cancer care, 
we support the implementation of COVID-19-specific strategies and their integration with NCD action plans at all governance levels. Such 
strategies have relevance during and beyond the pandemic to ensure the momentum of the WHO GICC is maintained. 
Regional response strategies where we can offer specific support
SARS-Cov2-specific measures:
• The accrual of objective evidence from multi-stakeholders and the broad community of the impact of COVID-19 to guide the mitiga-
tion of COVID-19 on childhood cancer treatment.
• The development of a reporting framework and research agenda on the impact of COVID-19 on childhood cancer care delivery, patient 
outcomes and workforce at all resource levels, with the aim to develop evidence-based best practice for clinical and care organisation 
decision-making. 
• The development of consensus-based recommendations during the pandemic for the ongoing care across all aspects of the paediat-
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• The development of evidence on strategies and guidelines for physicians, nurses and support staff to mitigate the risk of COVID-19 
transmission within the community, during transportation and at the medical facilities. These include isolation and screening proce-
dures for patients, families and visitors, quarantine for COVID-19-positive patients (while maintaining access to oncology services, 
support during the infection and continuation of cancer-curing therapies), staff training on PPE and infection control, cleaning and 
sanitation guidelines, deferment of non-urgent hospital and clinic visits using telehealth, satellite clinics, family psychosocial support 
and increased financial and logistical assistance for families in crisis.
Evidence-based adaptations to cancer care in high COVID-19 prevalence communities
• Provide guidance on the adaptation of treatment regimens across settings during the pandemic. 
• Highlight unmet needs in areas adjacent to care delivery, such as support of transportation and housing for families staying with their 
severely ill children during treatment, particularly in low- and middle-income countries.
• Consider the needs of children and young people with cancer in national cancer planning for COVID-19 recovery.
Ongoing evidence-based activities that must not be suspended during the pandemic and for which the pandemic may provide additional 
impetus for action
• Implementation of national awareness of childhood cancer early warning signs to ensure timely referral of children with suspected 
cancer, which could be combined with education about COVID-19 prevention and control.
• Diversification and reinforcement of global medication supply chains and streamlined regulatory procedures.
• Contingency planning for all critical oncology infrastructure in cases of outages. Radiation therapy, diagnostic imaging and other pro-
cedures that depend on potentially fragile equipment may lack access to routine service and maintenance if the service contractor is 
immobilised by the pandemic. Contingency planning and pre-established relationships with other facilities to provide services during 
outages not only protect patients during a pandemic, but during outages that occur for any other reason.
• Support institutional and government decisions on maintaining paediatric cancer as a priority within hospital structure, and preventing 
unnecessary delays in treatment (chemotherapy, surgery, radiotherapy, supportive and palliative care). If for any reason, delays should 
be necessary, they should be planned in a way as not to have impact on survival.
As we emerge from the pandemic health crisis, we strongly support the implementation of the WHO GICC. We will advocate with Health 
Ministries and Health Services to adopt recommendations in the WHO technical packages for the development of child and adolescent 
cancer services.
In particular we support the:
• Development of national child and adolescent cancer control plans.
• Sustained procurement and supply of essential cancer chemotherapy and supportive care medicines, including blood products, and 
medical devices 
• Maintenance of the momentum of the WHO GICC across all global regions in partnership with the WHO and other agencies.
Conclusion
As representatives of a wide range of childhood cancer health professionals and researchers, expert parent and survivor NGOs, and advo-
cates, the global paediatric cancer community stands ready to partner with national health services and government ministers in COVID-19 
mitigation programmes that promote the well-being of all children and adolescents, including those with cancer as a particularly vulnerable 
population with specific needs. We also wish to look beyond the current pandemic and support the wide implementation of the WHO GICC, 
to cure more and care for all, wherever they may live. We welcome the ongoing efforts of the WHO NCD Directorate to accelerate imple-
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